Alphamab Oncology
Alphamab Oncology, a leading biopharmaceutical company headquartered in China, is at the forefront of innovative cancer therapies. Founded in 2016, the company has rapidly established itself in the oncology sector, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics. With a strong presence in both domestic and international markets, Alphamab Oncology has achieved significant milestones, including the successful development of its proprietary drug candidates. Their core products, distinguished by their unique mechanisms of action, aim to address unmet medical needs in cancer treatment. Recognised for its commitment to advancing oncology solutions, Alphamab Oncology continues to strengthen its market position through strategic partnerships and a robust pipeline, making it a notable player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Alphamab Oncology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alphamab Oncology's score of 22 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alphamab Oncology's reported carbon emissions
In 2023, Alphamab Oncology reported total carbon emissions of approximately 12,760,810 kg CO2e, comprising 3,969,510 kg CO2e from Scope 1 and 8,791,300 kg CO2e from Scope 2 emissions. This marks a slight increase from 2022, where total emissions were about 11,462,820 kg CO2e, with Scope 1 at 3,605,450 kg CO2e and Scope 2 at 7,857,370 kg CO2e. The company has not disclosed any Scope 3 emissions data. Despite the increase in emissions, Alphamab Oncology has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company operates without cascading emissions data from a parent organization, maintaining its own reporting standards. Overall, while Alphamab Oncology's emissions reflect its operational scale, the lack of defined climate commitments highlights an area for potential improvement in its sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 75,810 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 798,260 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alphamab Oncology is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
